In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis

Authors:
  • LRLisa R. Reynolds
    Lisa R. Reynolds
  • SBSteven C. Budsberg
    Steven C. Budsberg

Abstract
Objective —To evaluate in vivo activity of carprofen, deracoxib, and etodolac on prostanoid production in several target tissues in dogs with chronic osteoarthritis. Animals —8 dogs with chronic unilateral osteoarthritis of the stifle joint. Procedure —Each dog received carprofen, deracoxib, or etodolac for 10 days with a 30- to 60-day washout period between treatments. On days 0, 3, and 10, prostaglandin (PG) E 2 concentrations were measured in lipopolysaccharide-stimulated blood, synovial fluid, and gastric mucosal biopsy specimens; PGE 1 concentrations were measured in gastric mucosal biopsy specimens; and thromboxane B 2 (TXB 2 ) was evaluated in blood. Results —Carprofen and deracoxib significantly suppressed PGE 2 concentrations in blood at days 3 and 10, compared with baseline, whereas etodolac did not. None of the drugs significantly suppressed TXB 2 concentrations in blood or gastric PGE 1 synthesis at any time point. All 3 drugs significantly decreased gastric synthesis of PGE 2 at day 3 but not day 10 of each treatment period. All 3 drugs decreased synovial fluid PGE 2 concentrations in the affected and unaffected stifle joints at days 3 and 10. Conclusions and Clinical Relevance —Results indicate that carprofen and deracoxib act in vivo on target tissues as COX-1–sparing drugs by sparing gastric PGE 1 and PGE 2 synthesis and production of TXB 2 by platelets. Etodolac also appears to be COX-1 sparing but may have variable effects on COX-2 depending on the tissue. In gastric mucosa and synovial fluid, there were no significant differences in PG production between compounds at recommended concentrations. ( Am J Vet Res 2005;66:812–817)

This publication has 25 references indexed in Scilit: